Oncolysin B immunoconjugate of mouse anti-CD19 antibody linked to ricin data

Ten of the 12 patients in a Phase I/II trial remain in complete remission, with median time from transplant of 33 months. Only 30 - 50 percent of these patients would be expected to be disease-free after two years, the company said. ...